Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Roche’s Imvigor-130 study supports Tecentriq’s continued use in urothelial bladder cancer – up to a point.
Aurinia hopes to light up with Aurora data, while Principia's BTK inhibitor PRN1008 is put to the test.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
With little cash in the bank and creditors soon to start pressing, a trial failure is a disaster for Viveve.
Cara Therapeutics’ stock shot up 18% today on data derisking two key projects.
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.